Therapeutic effects of umbilical cord blood plasma in a rat model of acute ischemic stroke
Metrics: PDF 908 views | HTML 1454 views | ?
Jongman Yoo1,*, Han-Soo Kim2,*, Jin-Ju Seo3, Jang-Hyoun Eom3, Seong-Mi Choi4, Sanghyun Park4, Dong-Wook Kim4, Dong-Youn Hwang1,3
1Department of Microbiology and Institute of Basic Medical Sciences, School of Medicine, CHA University, Seongnam, Kyeonggido 463-400, Korea
2Department of Biomedical Sciences, Catholic Kwandong University, Gangneungsi, Gangwondo 210-701, Korea
3Department of Biomedical Science, College of Life Science, CHA University, Seongnam, Kyeonggido 463-400, Korea
4Department of Physiology and Brain Korea 21 Plus Project for Medical Science, Yonsei University College of Medicine, Seoul 120-752, Korea
*These authors contributed equally to this work
Dong-Wook Kim, email: firstname.lastname@example.org
Dong-Youn Hwang, email: email@example.com
Keywords: stroke, umbilical cord plasma, ischemia, neuroinflammation, neurogenesis
Received: September 20, 2016 Accepted: October 24, 2016 Published: October 31, 2016
Umbilical cord blood plasma (UCB-PL) contains various cytokines, growth factors, and immune modulatory factors that regulate the proliferation and function of immune cells and adult stem cells. Despite its therapeutic potential, the effects of UCB-PL treatment in conditions of ischemic brain injury have yet to be investigated. In this study, we demonstrated that both behavioral and structural impairments resulting from ischemic brain injury were significantly prevented/reversed after intravenous administration of UCB-PL relative to the vehicle control. As early as 1-week post-ischemia, an increased number of newborn cells in the subventricular zone and a reduced number of activated microglial cells in the peri-infarct area were observed in the UCB-PL group, suggesting that enhanced neurogenesis and/or the suppression of inflammation may have contributed to functional protection/recovery. Moreover, UCB-PL was more effective than plasma derived from a 65-year-old healthy adult for the treatment of ischemia-related structural and functional deficits, indicating that UCB-PL had greater therapeutic potential. This study provides valuable insights into the development of a safe, effective, and cell-free strategy for the treatment of ischemic brain damage and a much-needed alternative for patients who are ineligible for thrombolytic therapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.